Apollo’s $145m financing will help advance its 15-plus candidate portfolio into clinical development. With Patient Square leading the round, its expertise with BridgeBio and co. will help guide Apollo’s evolution.

Dermatologists have compared the current market for vitiligo to that of psoriasis 30 years ago, which grew from one with a dearth of therapies to one worth about $8bn.

Vertex and partner CRISPR Therapeutics hope CDX001 can offer a single-use curative regimen for sickle cell disease and beta thalassemia patients. A regulatory filing is possible within 18-24 months.

Since raising $135m in 2017 to address rare, monogenic diseases, BridgeBio has launched or purchased 17 companies and built a pipeline of 30-plus candidates. Scrip checked in as the company nears commercialization.